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Abstract
Background: Moxibustion is an ancient traditional medicine using burning mugworts to stimulate acupuncture
points. The aim of this study was to investigate the safety and efficacy of moxibustion for the treatment of
constipation using a randomized, sham-controlled, participant-blinded, pilot trial.
Methods: Twenty-six participants (identified with either qi (vital energy) deficiency or qi excess syndrome) were
randomly divided into either a moxibustion or sham group. Participants were treated with real or sham
moxibustion at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks. The primary
outcome was the frequency of defecations; secondary outcomes were the Bristol stool form scale (BSS) and the
constipation assessment scale (CAS).
Results: Of the 26 participants that were randomized, 24 completed the study. Defecation frequency, BSS, and CAS
showed no difference between the moxibustion and sham groups. The differences were -0.25 (95% CI: -2.08, 1.58,
p = 0.78), -1.22 (95% CI: -2.7, 0.26, p = 0.1), 0.91 (95% CI: -1.46, 3.28, p = 0.44) in defecation frequency, BSS, CAS,
respectively. The defecation frequency increased from an average of 3.3 to 4.6 times per week in the moxibustion
group (1.5[-0.5, 2], p = 0.06) and from 2.7 to 3.7 stools per week in the sham group (1[-1, 2], p = 0.15) after four
weeks of treatment. The difference between participants with a deficiency or an excess syndrome, determined
based on assessment of sweat, facial features, pain, body energy, and pulse type, was significant in only defecation
frequency. The difference was 3.3 (95% CI: 0.41, 6.19, p = 0.03).
Conclusion: Moxibustion treatment appears safe, but showed no positive effect on constipation. The effectiveness
of moxibustion treatment may depend on the syndrome pattern, and further long-term studies with a larger
number of subjects are warranted.
Trial registration: Clinical Research Information Service, KCT0000168
Background
Constipation is a common gastrointestinal complaint that
is experienced by 27.2% of Canadians [1], 12%-19% of
Americans [2], and 14% of Asians [3], with a prevalence of
11.6% in the elderly Asian [4]. In Korea, the prevalence is
16.5% for self-reported constipation, 9.2% for functional
constipation and 3.9% for constipation-predominant irrita-
ble bowel syndrome [5].
Constipation can cause abdominal pain, discomfort,
gas, headache, nausea, and anorexia as well as potentially
contributing to functional loss and length of stay in the
hospital [6]. Patients spend approximately $7,900 a year
on health care costs for their constipation [7]. However,
many patients are disappointed by current conventional
treatments and seek help from complementary and alter-
native medicine practitioners [8].
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as traditional Chinese medicine (TCM). Acupuncture
and moxibustion are similar except that their stimula-
tion methods are different. Moxibustion uses the heat
generated by burning herbal preparations containing
Artemisia vulgaris to stimulate acupuncture points.
Moxibustion treatment, though uncommon in Western
countries, has been shown to have benefits for pain [9],
cancer care [10], and ulcerative colitis [11].
To date, there have been three randomized controlled
clinical trials (RCTs) testing the effectiveness of moxibus-
tion for the relief of constipation [12]. Previous RCTs
have shown that moxibustion treatment was more effec-
tive against constipation than a glycerin enema [13,14] or
no treatment [15]. However, the methodology used in
these studies may have had a risk of bias [12], and a clini-
cal trial comparing moxibustion with sham treatment
does not exist.
The aims of this rigorous, pilot patient-blinded RCT
are to evaluate the safety and efficacy of moxibustion
for the treatment of constipation by comparing moxi-
bustion and sham treatment.
Methods
Study design and ethics approval
This study was a single-center, randomized, parallel,
sham-controlled, patient-blinded pilot clinical trial to eval-
uate the safety and efficacy of moxibustion in subjects
with constipation in Korea. The Oriental Medical Doctor
(OMD) initially screened each potential participant against
the inclusion and exclusion criteria. After completing a
screening test, participants entered a one-week baseline
period without moxibustion treatment. At the end of the
baseline period, eligible subjects were randomized to either
the moxibustion or the sham group. The treatment period
consisted of one week of baseline assessment, four weeks
of treatment, and two weeks of follow-up, for a total study
period of seven weeks.
All participants were blinded to the type of treatment
received until completion of the study. To avoid allocation
bias, concealed allocation using a sealed envelope was
employed in this study. The study was conducted in accor-
dance with the Declaration of Helsinki, and written
informed consent was obtained from each participant
before allocation. The study was approved by the Institu-
tional Review Board of Daejeon University Hospital, Dae-
jeon, South Korea, where the study took place. Full details
of the trial protocol can be found at cris.cdc.go.kr [16].
Inclusion/exclusion criteria
The recruitment of subjects took place from May to Sep-
tember in 2009. The study subjects consisted of adults
aged 19 to 55 years with at least a six-month history of
constipation according to the Rome criteria [17]. To be
included in the study, participants had to have at least two
of the following symptoms on more than 25% of occa-
sions: straining; lumpy or hard stools; a sensation of
incomplete evacuation; a sensation of anorectal obstruc-
tion/blockage; manual maneuvers to facilitate defecation;
or defecation frequency less than three times per week.
Subjects were excluded from the study if they had
inflammatory bowel disease or other structural bowel dis-
eases, a diagnosis of irritable bowel syndrome (IBS), other
significant disorders or diseases that may interfere with
completion of the study, or used laxatives two weeks prior
to the baseline assessment. Pregnant or breastfeeding
women were excluded as were participants reporting more
than one loose or watery stool each day during the base-
line period. Magmil (Magnesium Hydroxide) was allowed
as a rescue medication for participants who had intoler-
able discomfort due to severe constipation, but use was
monitored.
Recruitment and randomization procedures
Participants were recruited through advertisements in local
newspapers and the hospital website and bulletin boards.
Candidates were interviewed and evaluated to determine
eligibility. Written informedc o n s e n tw a so b t a i n e df r o me l i -
gible candidates. A statistician randomized participants
using computer-generated random table in a 1:1 ratio with
block size 4, and clinical research coordinators (CRC)
assigned them by the random table to receive real moxi-
bustion or sham treatment.
Treatments
Moxibustion or sham treatment was applied three times
per week for four weeks (a total of 12 treatments). All
moxibustion treatments were applied to acupuncture
points at bilateral ST23 (Taiyi) and ST27 (Daju), as those
sites were included in the Stomach Meridian of Foot
Yangmyeong and have been shown to improve gastro-
intestinal function such as dyspepsia, abdominal pain and
constipation [18,19]. Four OMD, each having a national
license and practical experience of more than 5 years,
selected the acupuncture points, frequency of moxibus-
tion, number of session through consensus among them
after reviewing the major textbook of acupuncture and
moxibustion [18-20]. Participants in the treatment group
received moxibustion with a moxa pillar (0.6 × 20 mm,
Kihoang company, South Korea) 3 times at each point in a
single session.
Sham treatment was given by adding insulation below
the moxa pillar to prevent the transfer of heat from the
moxa pillar to the patient. The sham treatment looks
similar to the real moxibustion treatment in its appear-
ance and burning procedure; therefore, participants
were able to smell the smoke or observe the burning
moxa (Figure 1). The validity of this method was well
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study [21].
All moxibustion treatments were performed by the
same experienced OMD practitioner who has had at
least six years of training in acupuncture and moxibus-
tion therapy.
Assessment
The primary outcome was the change in the number of
defecations per week from baseline to after the treat-
ment period. Secondary outcomes included the Bristol
Stool Form Scale (BSS) and the Constipation Assess-
ment Scale (CAS). All assessments were conducted
weekly by a researcher in each treatment arm.
BSS is designed to classify the form of stool into seven
categories, from ‘separate hard lumps, like nuts (Type 1)’
to ‘watery, no solid pieces (Type 7)’ [22]. All participants
had to record their defecation frequency and stool form in
a diary format. At each visit, the diary was checked by an
assessor and supplemented if further details were required.
The CAS is an eight-item tool that assesses the univer-
sal characteristics of constipation and assigns a score for
constipation on a three point summated rating scale ran-
ging from 0 ‘no problem’ to 2 ‘severe problem’. The CAS
has 8 items, therefore total CAS score has ranged from 0
to 16 [23]. The characteristics of constipation listed on
this tool include ‘abdominal distension or bloating’,
‘change in amount of gas passed rectally’, ‘less frequent
bowel movement’, ‘oozing liquid stool’, ‘rectal fullness or
pressure’, ‘rectal pain with bowel movement’, ‘small
volume of stool’ and ‘being unable to pass stool’.
Syndrome pattern differentiation of deficiency and excess
syndromes
As constipation is considered to be caused by either a defi-
ciency or excess of qi in traditional medicine in China and
Korea, we developed questionnaires to differentiate
between the deficiency and excess syndromes based on a
validated previous study [24]. The questionnaire used in
this study to determine whether a patient had a deficiency
or an excess syndrome included an assessment of sweat,
facial features, stomach pain, oppressive pain, stuffiness,
body energy, duration of disease, and pulse type. A patient
with a deficiency syndrome has sunken, weak pulse,
whereas a patient with an excess syndrome has superficial
and broad pulse. The patients having symptoms such as a
pale face, heavy sweat, and depression were considered to
have a deficiency syndrome; the patients having symptoms
such as a swollen face, little sweat, and chest pressure
were considered to have an excess syndrome. Syndrome
pattern differentiation was conducted by an OMD before
randomization.
Statistical analysis
All data were entered into a data sheet twice and reviewed
to ensure accuracy. The analyst (a statistician, KWK) was
blinded to group allocation. Intent-to-treat (ITT) analyses
were conducted; missing data were replaced with the last
observation value carried forward (LOCF) method. One
subject in the moxibustion group was dropped after ran-
domization without any clinical data. Therefore, the ITT
was 12 in the moxibustion group and 13 in the sham
group. All data are summarized as mean ± standard devia-
tion (SD) in continuous data and as frequency (%) in
dichotomous data. An independent Student’s t-test was
used to analyze the baseline differences between groups
and to evaluate the effect of treatment on the mean
change in scores between baseline and week four for all
continuous variables. Paired Student’s t-test was used to
analyze the differences between the values at baseline and
week four for all continuous variables.
For sample size calculation, there was no previous clini-
cal trial to compare the moxibustion with sham moxibus-
tion, therefore, this study was designed as a pilot study to
calculate the appropriate sample size for future rigorous
randomized clinical trials. Each group was considered 13
participants as minimum sample size for evaluating the
effect of moxibustion [25,26].
Statistical analyses were performed using the SAS sta-
tistical package (v.9.1, SAS institute, Inc., Cary, NC,
Figure 1 Diagram and appearance of the moxibustion (A) and
sham (B).
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p = 0.05.
Results
Demographic data
Thirty-three were screened for inclusion in this study by
CRCs from July to September 2009. Seven of these sub-
jects were excluded; five did not meet the inclusion cri-
teria (three had taken a prohibited drug, and 2 did not
meet the functional constipation criteria) and two with-
drew written informed consent. The remaining 26 partici-
pants were randomized into either the moxibustion
group (n = 13) or the sham group (n = 13); 24 completed
all treatments and the follow-up period. Two participants
of the moxibustion group, withdrew without completing
the study, one due to an adverse event and one due to an
inability to complete all treatment (Figure 2). All of the
participants were women. The demographic data were
not significantly different between the moxibustion and
sham groups (Table 1).
Primary outcome variable
There was no significant difference in the change in
defecation frequency between the moxibustion and
sham groups. The difference taking the change of moxi-
bustion group from that of sham group was -0.25 (95%
CI: -2.08, 1.58, p = 0.78). Defecation frequency increased
from an average of 3.3 to 4.6 times per week in the
moxibustion group and from 2.7 to 3.7 stools per week
in the sham group after four weeks of treatment.
The moxibustion group showed differences in defeca-
tion frequency that approached significance when com-
pared to the baseline values (1.5[-0.5, 2], p = 0.06), but
the sham group showed no significant difference after
treatment (1[-1, 2], p = 0.15). (Figure 3, Table 2).
Secondary outcome variables
The difference in the change in the BSS score between the
moxibustion and sham group was -1.22 (95% CI: -2.7,
0.26, p = 0.1) in weeks 4, and -0.56 in weeks 6 (95% CI:
-1.76, 0.64, p = 0.34). The difference in the CAS score
between the two groups was 0.91 (95% CI: -1.46, 3.28, p =
0.44) in weeks 4, and 0.52 (95% CI: -2.02, 3.06, p =0 . 6 8 )i n
weeks 6 (Table 2).
However, when compared to baseline the moxibustion
group had a significant change in BSS score after the 2
weeks of follow-up (0.45 [-0.04, 1], p = 0.048). The change
in CAS from baseline was significant in both the moxibus-
tion (-3 [-4.5, 0], p < .01 in 2 weeks, -4 [-5.5, -3], p < .001
in 4 weeks, and -4.5 [-6.5, -1], p < .01 in 6 weeks) and
sham (-4 [-5, -3], p < 0.001 in 2 weeks, -4 [-4, -1], p < .01
in 4 weeks, -3 [-4, -1], p < .001 in follow-up) treatment
groups.
Syndrome pattern differentiation of deficiency and excess
syndromes
Five participants were diagnosed with an excess syn-
drome, and twenty-one participants were diagnosed with
a deficiency syndrome. In this study, the most prevalent
symptoms for an excess syndrome were a strong body
energy and superficial pulse; for a deficiency syndrome
the symptoms were a long duration of disease and weak
body energy.
Of the participants who received moxibustion treatment,
ten of 13 were diagnosed with a deficiency syndrome.
There were no significant differences between the partici-
pants with a deficiency or an excess syndrome at baseline
in terms of the demographic data and constipation symp-
toms, including defecation frequency, BSS and CAS score.
In the defecation frequency, moxibustion treatment
showed significantly greater effect on participants with an
excess syndrome than those with a deficiency syndrome.
The difference was 3.3 (95% CI: 0.41, 6.19, p = 0.03). How-
ever, neither the BSS nor CAS scores were significantly
different between these two groups after moxibustion
treatment. The difference between two groups was 0.33
(95% CI: -1.54, 2.19, p = 0.70) in BSS and -1.4 (95% CI:
-5.71, 2.91, p = 0.49) in CAS (Table 3, Figure 4).
Safety
There were no serious adverse events reported during the
study period. Two participants in the moxibustion group
and one participant in the sham group reported rubefac-
tion with or without an itching sensation. Only one
patient in the moxibustion group dropped out due to this
adverse event. All adverse events reported in this study
were mild and transient.
Discussion
Our study is the first rigorous randomized, sham-con-
trolled, patient blinded clinical trial to evaluate the safety
and efficacy of moxibustion for the treatment of consti-
pation in adults. These study results suggest that moxi-
bustion treatment showed no improved effects on
constipation than sham treatment.
T h e r ea r ean u m b e ro fp o s s i b l ei n t e r p r e t a t i o n sf o r
these findings. First, moxibustion treatment may truly
have had no effect on the treatment of constipation. Sec-
ond, the small sample size may have contributed to the
lack of an observed effect even with a large SD [27].
Third, the moxibustion treatment design may not have
been optimal for the treatment of constipation in terms
of acupuncture points, treatment frequency, and the
number of treatment sessions. Fourth, the sham treat-
ment itself may have had unexpected effects on the treat-
ment of constipation rather than no effect at all. Though
there is a study validating this method of sham treatment
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Table 1 Demographic data of moxibustion and sham groups at baseline
Moxibustion
(n = 12)
Sham (n = 13) p-value
Sex (female (%)) 12 (100) 13 (100) 1.00
Age (years) 36.15 ± 15.24 37.08 ± 11.58 0.65
Height (cm) 158.83 ± 3.76 158.0 ± 4.73 0.63
Weight (kg) 52.67 ± 3.26 59.15 ± 10.31 0.05
Temperature (°C) 36.58 ± 0.19 36.40 ± 0.70 0.40
Blood pressure
(mm Hg)
Systolic 103.69 ± 10.56 109.77 ± 9.27 0.25
Diastolic 64.27 ± 10.30 64.85 ± 7.72 0.88
Pulse (beats/min) 77.36 ± 9.18 72.92 ± 6.95 0.19
Stool frequency (number/week) 3.33 ± 1.61 2.69 ± 1.38 0.39
BSS 3.07 ± 1.13 3.97 ± 1.08 0.06
CAS 7.25 ± 3.55 8.08 ± 2.36 0.50
Values are mean ± standard deviation. BSS: Bristol stool form scale; CAS: constipation assessment scale.
p-value, by independent Student’s t-test.
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as adverse event in our trial.
In practice, the treatment effect of moxibustion con-
sists of many factors, such as heat stimulation, the ingre-
d i e n t so ft h em o x ap i l l a r ,m o x as m o k ea n dt h et o u c h
sensation when moxibustion is applied on the acupunc-
ture points. Even though the moxa pillar was blocked in
the sham treatment to prevent the delivery of heat and
the ingredients of the moxa pillar, the touch sensation on
acupoints and the smoke from the pillar could have had
some positive or placebo effects.
In Oriental medicine, the diagnosis and treatment of a
patient is dependent on the condition and symptoms of
the patient. Even if patients have the same disease, they
may be treated differently based on their syndrome pat-
tern. This differentiation of syndromes is an important
characteristic of Oriental medicine [28].
The subjects of this study with an excess syndrome
were diagnosed as having excess-cold syndrome. Usually,
a deficiency syndrome accompanies a cold syndrome,
and an excess one accompanies a heat syndrome. But
some subjects are diagnosed as excess-cold by syndrome
pattern diagnosis. Moxibustion treatment might have dif-
fering roles according to the syndrome pattern. However,
the sample size was too small to evaluate the effect of the
syndrome pattern.
In addition, small sample could cause type II error, so
it could underestimate the effect of moxibustion.
Further studies are warranted with larger sample sizes
and more clear criteria for excess and deficiency syn-
dromes. Another shortcoming is we did not check
whether blinding was successful or not, though this
sham blinding method was well established as blinded
to the participants in a previous study [21]. Also, Asses-
sors were not blinded, because CRCs evaluated the
change of defecation frequency, BSS, and CAS scores, as
assessor.
In our study, it could make it difficult to apply these
results to the general population of constipated patients
because all participants are female. However, it could
also strengthen the validity of the differences between
the treatment and control groups due to the lack of a
gender bias.
Previously reported adverse events related to moxibus-
tion treatment include burns, an itching sensation, infec-
tion, allergy and xerophthalmia [29]. In patients with
constipation, a previous RCT reported itching, skin
eruption, and stinging eyes from the smoke as adverse
events [15]. All adverse events in this study were rube-
faction with or without itching and were reported as
mild.
This study is the first sham-controlled trial using
moxibustion for functional constipation. However, it has
several limitations as follows: small sample size, criteria
for syndrome differentiation, patient and assessor blind-
i n g .F u r t h e rs t u d i e sw i t hl a r g es a m p l es i z ea n db l i n d i n g
are needed. Also, more rigorous and validated sham
moxibustion should be developed.
Figure 3 Defecation frequency in moxibustion and sham
groups. All p-value > 0.05, by independent t-test.
Table 2 Effects of treatment between moxibustion and sham groups
Pre- and post-treatment
Baseline Week 2 Week 4 Week 6
Moxibustion
(n = 12)
Sham
(n = 13)
p Moxibustion
(n = 12)
Sham
(n = 13)
p Moxibustion
(n = 12)
Sham
(n = 13)
p Moxibustion
(n = 12)
Sham
(n = 13)
p
Defecation
Frequency
(times/week)
3.33 ± 1.61 2.69 ±
1.38
†0.39 3.67 ± 2.10 3.85 ±
1.68
0.38 4.58 ± 2.39 3.69 ±
1.93
0.78 4.08 ± 1.56 3.15 ±
1.34
†0.62
BSS 3.07 ± 1.13 3.97 ±
1.08
0.05 3.37 ± 1.19 4.36 ±
1.57
0.87 3.69 ± 1.29 3.36 ±
1.70
0.10 3.53 ± 1.25 3.86 ±
1.35
0.34
CAS 7.25 ± 3.55 8.08 ±
2.36
0.50 4.67 ± 3.20 3.85 ±
1.46
0.09 3.42 ± 2.15 5.15 ±
3.87
0.44 3.50 ± 3.90 4.85 ±
3.46
0.68
Values are mean ± standard deviation. BSS: Bristol stool form scale; CAS: constipation assessment scale.
p-value, by independent t-test.
† analyzed by Wilcoxon rank-sum test
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In conclusion, moxibustion treatment did not present
statistically significant effects when compared to sham
treatment in terms of the defecation frequency, the stool
form and subjective constipation symptoms. More rigor-
ous studies with a larger sample size are needed to ver-
ify if there is an effect of moxibustion on constipation.
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